Skip to main content

Table 2 Patient Demographic and Baseline Characteristics (Safety Population)

From: The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

Patient Demographic and Schizophrenia Characteristics

Cariprazine

1.5–3 mg/d

n = 170

Cariprazine

4.5–6 mg/d

n = 361

Cariprazine

9 mg/d

n = 148

Cariprazine

Overall

N = 679

Age, mean (SD), years

40.2 (10.6)

37.9 (10.8)

38.0 (11.2)

38.5 (10.9)

Male, n (%)

123 (72.4)

249 (69.0)

99 (66.9)

471 (69.4)

Race, n (%)

 White

71 (41.8)

174 (48.2)

57 (38.5)

302 (44.5)

 Black

64 (37.6)

116 (32.1)

60 (40.5)

240 (35.3)

 Asian

17 (10.0)

57 (15.8)

24 (16.2)

98 (14.4)

 Other

8 (4.7)

10 (2.8)

6 (4.1)

24 (3.5)

 Missinga

10 (5.9)

4 (1.1)

1 (0.7)

15 (2.2)

Weight, mean (SD), kg

79.26 (19.15)

77.13 (19.15)

82.69 (22.81)

78.88 (20.09)

Body mass index (BMI), mean (SD), kg/m2

26.96 (5.56)

26.32 (5.43)

27.82 (6.26)

26.81 (5.68)

Duration of schizophrenia, mean (SD), years

12.9 (10.0)

11.4 (9.5)

13.5 (9.9)

12.2 (9.8)

Age at onset, mean (SD), years

27.2 (9.4)

26.4 (9.2)

24.4 (8.6)

26.2 (9.1)

  1. a Race data were not collected in patients from Romania in study RGH-MD-11 per local regulations